Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

AbstractPurpose:. Pelareorep (Pel) is a type 3 oncolytic reovirus that upregulates PD-L1 expression. We determined the objective response rate (ORR) with paclitaxel (Pac), Pac + Pel, or Pac + Pel + ...

AbstractCisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the main treatment for muscle-invasive bladder cancer (MIBC). However, low survival rates highlight the necessity for ...

Tumor initiation, via either chemical mutagens or genetic models of Ras activation, produces long-lived, but latent, mutated cells that require chronic tumor promoter exposure to form cancers.

AbstractFocal amplifications of oncogenes are important cancer drivers. They can occur on chromosomes or in the context of circular extrachromosomal DNA (ecDNA). Many key features of ecDNAs were ...

AbstractPurpose:. The incidence of human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HPV + HNSCC) is increasing in the United States. Currently, there are no early detection ...

FADD promotes progression of tumors with chr11q13.3 amplification by binding to the DNA helicase complex, which can be targeted in combination with cyclin D1 as a viable therapeutic strategy for HNSCC ...

Disseminated cancer cells (DCCs) in the bone marrow (BM) can drive breast cancer metastasis. The authors show that intratumoral priming of antitumor CD4+ Th1 cells eradicates DCCs in the BM, ...

Abstract. The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for ...

Abstract. Cancer-associated cachexia (CAC) is a chronic wasting disease typically associated with advanced cancer, resulting in progressive and debilitating loss of function and poor tolerance to ...

Abstract. The combination of Antibody-Drug Conjugates (ADCs) and Immuno-Oncology (IO) agents is regarded as one of the most exciting and promising trends in the rapidly evolving field of cancer ...

We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, ...